Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin

Yulin Ma, Vijayabaskar Lakshmikanthan, Ronald W. Lewis, M. Vijay Kumar

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Due to its specificity and effectiveness, tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) is being tested for cancer therapy. Inhibition of the function of heat shock protein 90 (HSP90) is under clinical trials for cancer therapy. However, some cancer cells are resistant to TRAIL, and at the dose required for inducing apoptosis, geldanamycin, a drug that inhibits HSP90 function, has shown adverse effects. Therefore, our working plan was to identify a sublethal dose of geldanamycin and combine it with TRAIL to induce apoptosis in TRAIL-resistant prostate cancer cells. Treatment of LNCaP with 250 nmol/L geldanamycin inhibited HSP90 function but did not induce significant apoptosis. However, combination of geldanamycin and TRAIL induced highly significant apoptosis in TRAIL-resistant LNCaP cells. In addition to inducing caspase activity and apoptosis, treatment with geldanamycin and TRAIL decreased inhibitor of κB (IκB) kinase (IKK) complex proteins, IKKα, IKKβ, and IKKγ. The loss of IKK affected IκBα/nuclear factor-κB (NF-κB) interaction and reduced nuclear transport of NF-κB, resulting in reduced NF-κB activity. Our data show increase in apoptosis using low, suboptimal dose of geldanamycin when used with TRAIL. These results provide a means to alleviate two problems: resistance to TRAIL and adverse effects of high-dose geldanamycin.

Original languageEnglish (US)
Pages (from-to)170-178
Number of pages9
JournalMolecular cancer therapeutics
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

HSP90 Heat-Shock Proteins
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
geldanamycin
Neoplasms
Cell Nucleus Active Transport
Caspases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. / Ma, Yulin; Lakshmikanthan, Vijayabaskar; Lewis, Ronald W.; Kumar, M. Vijay.

In: Molecular cancer therapeutics, Vol. 5, No. 1, 01.01.2006, p. 170-178.

Research output: Contribution to journalArticle

Ma, Yulin ; Lakshmikanthan, Vijayabaskar ; Lewis, Ronald W. ; Kumar, M. Vijay. / Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. In: Molecular cancer therapeutics. 2006 ; Vol. 5, No. 1. pp. 170-178.
@article{4aecc956462845c9a6b2711fcc2e5c8e,
title = "Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin",
abstract = "Due to its specificity and effectiveness, tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) is being tested for cancer therapy. Inhibition of the function of heat shock protein 90 (HSP90) is under clinical trials for cancer therapy. However, some cancer cells are resistant to TRAIL, and at the dose required for inducing apoptosis, geldanamycin, a drug that inhibits HSP90 function, has shown adverse effects. Therefore, our working plan was to identify a sublethal dose of geldanamycin and combine it with TRAIL to induce apoptosis in TRAIL-resistant prostate cancer cells. Treatment of LNCaP with 250 nmol/L geldanamycin inhibited HSP90 function but did not induce significant apoptosis. However, combination of geldanamycin and TRAIL induced highly significant apoptosis in TRAIL-resistant LNCaP cells. In addition to inducing caspase activity and apoptosis, treatment with geldanamycin and TRAIL decreased inhibitor of κB (IκB) kinase (IKK) complex proteins, IKKα, IKKβ, and IKKγ. The loss of IKK affected IκBα/nuclear factor-κB (NF-κB) interaction and reduced nuclear transport of NF-κB, resulting in reduced NF-κB activity. Our data show increase in apoptosis using low, suboptimal dose of geldanamycin when used with TRAIL. These results provide a means to alleviate two problems: resistance to TRAIL and adverse effects of high-dose geldanamycin.",
author = "Yulin Ma and Vijayabaskar Lakshmikanthan and Lewis, {Ronald W.} and Kumar, {M. Vijay}",
year = "2006",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-05-0129",
language = "English (US)",
volume = "5",
pages = "170--178",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin

AU - Ma, Yulin

AU - Lakshmikanthan, Vijayabaskar

AU - Lewis, Ronald W.

AU - Kumar, M. Vijay

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Due to its specificity and effectiveness, tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) is being tested for cancer therapy. Inhibition of the function of heat shock protein 90 (HSP90) is under clinical trials for cancer therapy. However, some cancer cells are resistant to TRAIL, and at the dose required for inducing apoptosis, geldanamycin, a drug that inhibits HSP90 function, has shown adverse effects. Therefore, our working plan was to identify a sublethal dose of geldanamycin and combine it with TRAIL to induce apoptosis in TRAIL-resistant prostate cancer cells. Treatment of LNCaP with 250 nmol/L geldanamycin inhibited HSP90 function but did not induce significant apoptosis. However, combination of geldanamycin and TRAIL induced highly significant apoptosis in TRAIL-resistant LNCaP cells. In addition to inducing caspase activity and apoptosis, treatment with geldanamycin and TRAIL decreased inhibitor of κB (IκB) kinase (IKK) complex proteins, IKKα, IKKβ, and IKKγ. The loss of IKK affected IκBα/nuclear factor-κB (NF-κB) interaction and reduced nuclear transport of NF-κB, resulting in reduced NF-κB activity. Our data show increase in apoptosis using low, suboptimal dose of geldanamycin when used with TRAIL. These results provide a means to alleviate two problems: resistance to TRAIL and adverse effects of high-dose geldanamycin.

AB - Due to its specificity and effectiveness, tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) is being tested for cancer therapy. Inhibition of the function of heat shock protein 90 (HSP90) is under clinical trials for cancer therapy. However, some cancer cells are resistant to TRAIL, and at the dose required for inducing apoptosis, geldanamycin, a drug that inhibits HSP90 function, has shown adverse effects. Therefore, our working plan was to identify a sublethal dose of geldanamycin and combine it with TRAIL to induce apoptosis in TRAIL-resistant prostate cancer cells. Treatment of LNCaP with 250 nmol/L geldanamycin inhibited HSP90 function but did not induce significant apoptosis. However, combination of geldanamycin and TRAIL induced highly significant apoptosis in TRAIL-resistant LNCaP cells. In addition to inducing caspase activity and apoptosis, treatment with geldanamycin and TRAIL decreased inhibitor of κB (IκB) kinase (IKK) complex proteins, IKKα, IKKβ, and IKKγ. The loss of IKK affected IκBα/nuclear factor-κB (NF-κB) interaction and reduced nuclear transport of NF-κB, resulting in reduced NF-κB activity. Our data show increase in apoptosis using low, suboptimal dose of geldanamycin when used with TRAIL. These results provide a means to alleviate two problems: resistance to TRAIL and adverse effects of high-dose geldanamycin.

UR - http://www.scopus.com/inward/record.url?scp=33644857988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644857988&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0129

DO - 10.1158/1535-7163.MCT-05-0129

M3 - Article

C2 - 16432176

AN - SCOPUS:33644857988

VL - 5

SP - 170

EP - 178

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -